Study of OT202 in Treating Moderate to Severe Dry Eye

NCT06435182 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

DRUG: OT202 conc 0.5%
DRUG: OT202 conc 0.1%
DRUG: Placebo

Sponsor

Ocumension Therapeutics (Shanghai) Co., Ltd